214370

CAREGEN is a biotechnology company that researches, develops, and manufactures biomimetic peptides and growth factor proteins. The company applies these bioactive ingredients across four main business segments: health functional foods, medical devices, cosmeceuticals, and pharmaceuticals. In the health food sector, CAREGEN produces peptide-based supplements for blood sugar regulation, muscle health, and weight management, including products like ProGsterol, MyoKi, and Korglutide. Its medical device portfolio consists of Class III medical devices for medical aesthetics, such as dermal fillers, hair fillers, and mesotherapy products under brands like REVOFIL, Dermaheal, and DR.CYJ. The cosmeceutical division offers functional skincare and haircare products targeting skin aging, pigmentation, and hair loss. CAREGEN is also developing peptide-based pharmaceutical candidates for ophthalmic diseases, including CG-P5 for wet age-related macular degeneration and CG-T1 for dry eye disease. The company supplies functional peptide raw materials to global partners, including an exclusive supply agreement with BASF. CAREGEN sells its products globally through exclusive and non-exclusive distributors, with a significant portion of revenue derived from exports. The company was founded in 2001 and maintains a large peptide library with numerous registered patents.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage caregen.co.kr
Sector Healthcare IR page caregen.co.kr
Tags
biomimetic peptides, growth factors, health functional foods, medical aesthetics, dermal fillers, mesotherapy, cosmeceuticals, ophthalmic therapeutics, peptide raw materials, metabolic health, hair care, skin care, ProGsterol, MyoKi, Korglutide, Deglusterol, CG-P5, CG-T1, CG-EGF, CG-Purilux, REVOFIL, Dermaheal, DR.CYJ, Prostrolane, Intracisc, Linevisc, Aquashine, Pelo Baum, Luxidase, BASF
Press page —

Metrics

Valuation  
Market cap ₩ 2.149T
Market cap (USD) $ 923.102M
P/E 49.89
PEG —
P/BV 9.83
P/S 28.69
P/OCF 82.18
P/FCF 96.77
Dividend yield —
Turnover / mcap —
Returns  
ROE 9.2%
ROI 9.5%
ROIC 8.6%
Profit margin 27.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -9.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2013
Revenue 72.808B 82.586B 79.21B 69.098B 59.088B 60.295B 64.699B 51.211B 46.531B 30.905B 30.234B —
Net profit 20.099B 32.314B 39.93B 27.267B 25.318B 31.478B 28.07B 16.491B 18.426B 11.569B 12.811B —
Free cash flow 14.729B -52.38B 20.447B -29.225B 47.97B 9.696B 63.5B -9.097B 42.307B -19.955B — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2013
Share price 30.55K 24K — — — — — — — — — —
Price performance 12m 0.27 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 2.42B 3.47B 2.14B 2.55B 4.88B 5.54B 6.95B 13.1B 33B 30B
↳ YoY growth -43.0% +43.4% -38.3% +19.2% +91.1% +13.5% +25.5% +89.1% +150.8% -9.0%
↳ 5y CAGR -10.9% -7.0% +2.8% +18.0% +14.9% +43.8% +66.8% +43.8%
Cash and deposits (KRW) 70.5B 50B 17.5B 21.7B 16B 22.2B 5.18B 31.5B 5.07B 8.86B
Intangible assets (KRW) 1.24B 1.34B 1.42B 1.76B 2.22B 3.06B 3.92B 4.69B 4.95B 5.06B
Cash flow detail
Operating cash flow (KRW) -16B 47.9B -6.82B 69.7B 30.8B 51.9B -27.7B 28.6B 13.5B 18.6B
Purchases of property, plant and equipment (KRW) -4B -5.57B -2.28B -6.16B -21.1B -3.89B -1.54B -8.16B -65.9B -3.86B
Purchases of intangible assets (KRW) -302M -337M -515M -1.34B -740M -1.38B -1.48B -1.54B -1.1B -1.06B
Dividends paid (cash effect) (KRW) -6.43B -16.4B -12.3B 0.00 -34.7B -20.6B -24.5B -28.5B -31.4B -31.1B
Share buybacks (cash effect) (KRW) -33.5B -6.13B -6.19B -14.3B -8.58B — — — -5.03B —
Interest paid (cash effect) (KRW) — — 0.00 0.00 -4.44M — — — — —
Income taxes paid (cash effect) (KRW) -6.03B -7.69B -8.23B -10.4B -5.91B -2.17B -8.68B -6.45B -12.1B -5.77B
Free cash flow (OCF - PPE - intangibles) (KRW) -20.3B 42B -9.61B 62.2B 8.96B 46.6B -30.7B 18.9B -53.5B 13.7B
Income detail
Total comprehensive income (KRW) — 13.7B 17.7B 26.5B 31.4B 25B 28.1B 39.7B 32.2B 20.6B
Comprehensive income to owners (KRW) 13.2B 14.3B 18B -50.7M 31.5B 25.1B 28.1B 39.7B 32.2B 20.6B
Reported Apr 29, 2020 Apr 29, 2020 Mar 19, 2021 Mar 19, 2021 Mar 19, 2021 Mar 11, 2024 Mar 11, 2024 Mar 11, 2024 Mar 17, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Routine
주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

CAREGEN (ticker 214370), listed in South Korea.

ETFs Holding CAREGEN

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 1,833 $ 37.674K Nov 16, 2026
DEXC 0.02% 2,087 $ 44.314K Nov 12, 2026
DFSE 0.01% 1,850 $ 39.282K Nov 12, 2026
DFEM 0.00% 17,623 $ 374.197K Nov 12, 2026
DFAX 0.00% 9,011 $ 191.334K Nov 12, 2026
DFAE 0.00% 6,450 $ 136.956K Nov 12, 2026
AVEM 0.00% 12,678 $ 260.57K Nov 16, 2026